Tokyo, May 26, 2006 (JCN) - Translational Research, a subsidiary of Shin Nippon Biomedical Laboratories, has developed an intranasal formulation of granisetron, an agent with antiemetic efficacy.
Granisetron is commonly used in reducing side effects of antitumor therapy. In experiments on monkeys, the company confirmed that the new formulation has an immediate action equivalent to injections as well as excels in absorbability through nasal mucosa.
The company expects that the new formulation may help improving the quality of life of cancer patients suffering from side effects.
Going forward, the company plans to begin phase I clinical trials with a view to commercializing it around 2010.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
|
